CytoReason vs Medial EarlySign
CytoReason vs Medial EarlySign, compared side by side on 19 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: CytoReason is on 68/100 and Medial EarlySign on 49/100.
Where each one leads
CytoReason
- our overall score: 68/100 against 49/100
- domain rating: 40/100 against 31/100
- headcount: 116 against 8
- headcount growth: +13.7% against -26.4%
- funding raised: $128M against $50.0M
- LinkedIn following: 12,830 against 2,122
Medial EarlySign
Leads on none of the measures we hold for both companies.
At a glance
| Measure | CytoReason | Medial EarlySign |
|---|---|---|
| What it is | Develops a computational model of the human body for drug discovery and development. | Develops AI-powered decision support tools for personalized medical data interpretation and prediction. |
| Category | Healthcare, Drug Discovery, Clinical Development, Biomarkers | Healthcare, Decision Support, Insights, Detection |
| Sells toBusiness model | B2B | B2B |
| Offering | Software | Software |
| Founded | 2016 | 2009 |
| Headquarters | Tel Aviv, Israel | Tel Aviv, Israel |
| Status | Active | Inactive |
Size, funding and growth
| Measure | CytoReason | Medial EarlySign |
|---|---|---|
| Employees | 116 | 8 |
| Headcount growthLast 12 months | +13.7% | -26.4% |
| Total funding | $128M | $50.0M |
| Latest round | Series B | Series B |
| LinkedIn followers | 12,830 | 2,122 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | CytoReason | Medial EarlySign |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 68/100 | 49/100 |
| Traction | 60/100 | 48/100 |
| Team | 70/100 | 20/100 |
| Community | Not published | 15/100 |
| Search visibility | 30/100 | 29/100 |
| Quality | 78/100 | 58/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (21/100) | F (22/100) |
| Domain ratingLink authority, 0-100 | 40/100 | 31/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | CytoReason | Medial EarlySign |
|---|---|---|
| Analytics | Segment | Not detected |
CytoReason vs Medial EarlySign: common questions
Which is better, CytoReason or Medial EarlySign?
On our 0-100 score CytoReason rates higher (68/100 against 49/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 19 data points above: read the rows that match what you are buying for.
How do CytoReason and Medial EarlySign compare on the numbers?
CytoReason leads on our overall score (68/100 against 49/100), domain rating (40/100 against 31/100), headcount (116 against 8), headcount growth (+13.7% against -26.4%), funding raised ($128M against $50.0M), LinkedIn following (12,830 against 2,122).
Read the full CytoReason review and pricing or the Medial EarlySign review and pricing. You can also browse other CytoReason alternatives we track.